Wu Ruchen, Chen Junze, Wang Gang, Han Lulu
Cancer Institute, Xuzhou Medical University, Xuzhou, Jiangsu, China.
Center of Clinical Oncology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China.
Front Oncol. 2025 Aug 15;15:1609840. doi: 10.3389/fonc.2025.1609840. eCollection 2025.
Cancer immunotherapy represents a paradigm shift in oncology by leveraging the immune system to target tumors. The therapeutic efficacy of these approaches depends critically on identifying molecular targets that enhance treatment responses while limiting toxicity. CD70, a TNF family member, has emerged as a promising target due to its overexpression in hematologic malignancies and solid tumors contrasted with restricted expression in healthy tissues. This differential expression profile implies that CD70-directed therapies could achieve tumor-specific cytotoxicity with reduced off-target effects. Nevertheless, key challenges persist, including optimizing delivery systems and elucidating the immunological consequences of CD70 modulation. This review synthesizes recent progress in CD70-targeted immunotherapy, evaluating both its therapeutic potential and current constraints to guide future clinical translation.
癌症免疫疗法通过利用免疫系统靶向肿瘤，代表了肿瘤学领域的一种范式转变。这些方法的治疗效果关键取决于识别能够增强治疗反应同时限制毒性的分子靶点。CD70是一种肿瘤坏死因子家族成员，由于其在血液系统恶性肿瘤和实体瘤中过度表达，而在健康组织中表达受限，已成为一个有前景的靶点。这种差异表达谱意味着针对CD70的疗法可以实现肿瘤特异性细胞毒性，同时减少脱靶效应。然而，关键挑战仍然存在，包括优化递送系统以及阐明CD70调节的免疫后果。本综述综合了CD70靶向免疫疗法的最新进展，评估了其治疗潜力和当前的限制，以指导未来的临床转化。
